NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

文章核心观点 - DexCom公司在2024年第二季度的财务业绩和全年收入指引低于预期 [1] - 公司将此归咎于"几项关键战略举措"的执行未达预期标准 [1] - 公司股价在2024年7月26日下跌约40.66% [1] 公司信息 - DexCom公司是一家医疗设备公司,主要从事糖尿病监测设备的研发和生产 [1] - 公司股票代码为DXCM,在纳斯达克上市 [1] 投资者诉讼 - 投资者在2024年1月8日至7月25日期间购买DexCom股票的,被鼓励联系律师事务所,可能成为集体诉讼的代表原告 [1][2] - 集体诉讼的指控是公司在2024年7月25日发布的财报和收入指引低于预期,导致股价大跌 [1] - 投资者如果参与此集体诉讼,无需支付任何费用 [2]

NEW YORK, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline in the securities class action. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plainti ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=100122&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

会议主要讨论的核心内容 - 公司认为CGM市场仍是一个高增长市场 CGM渗透率在美国Type 1糖尿病患者中达60%-65%、Type 2重症患者中达50%-55%、基础胰岛素患者中达20%-25%,而非重症Type 2糖尿病患者市场还有很大机会 [2][3] - 公司正在采取措施应对竞争对手Abbott在某些细分市场的优势 包括加强销售团队管理、与主要分销商建立更紧密的合作关系 [4][5][6][7] - 公司计划在2025年推出15天使用期的G7产品 已经提交FDA审批 [8][9][10][11] - 公司长期增长目标仍然是15%-20% 尽管短期内受到一些执行问题的影响 [15][16][17] 问答环节重要的提问和回答 - 分析师关注公司在DME分销渠道的市场份额下降 公司表示是由于销售团队调整和渠道中性策略执行不力造成的 正在采取措施加强与DME分销商的合作关系 [20][21][22][23][24][25][26][27] - 分析师关注公司在Medicare Advantage患者群体中的表现 公司表示这主要是由于销售团队在推广渠道中性策略时出现偏差 正在纠正这一问题 [29][30][31][32] - 分析师对Stelo产品的市场反响和定价策略提出询问 公司表示初期反响良好 正在收集用户反馈并优化产品体验 定价策略经过充分市场调研 未来会根据市场情况适当调整 [48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67] - 分析师对公司2025年的财务目标提出质疑 公司表示主要依靠销售团队的提升、Stelo产品的贡献以及国际市场的增长来实现 [68][69][70][71][72][73]

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...